ContraFect Corporation ContraFect Corporation Nasdaq: CFRX

Navigate ContraFect Corporation

  • Home
  • About Us
    • Overview
    • Management Team
    • Board of Directors
  • Technology
    • Overview
    • Lysins
    • Monoclonal Antibodies
    • Publications / Posters
    • Video Library
  • Pipeline
    • Overview
    • CF-301
    • Gram-negative Lysins
    • CF-404
  • Investors & Media
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Careers
  • Contact Us

Press Releases

Investors & Media

  • Home
  • Investors & Media
  • News / Events
  • Press Releases
Investors & Media

Investors & Media

  • Overview
  • News / Events
    • Press Releases
    • Events & Presentations
    • Email Alerts
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
  • All News
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010

ContraFect to Present at Two Upcoming Investor Conferences

September 20, 2018

ContraFect Completes Enrollment in Phase 2 Clinical Trial Evaluating CF-301 (exebacase) in Patients with Staphylococcus Aureus Bacteremia

September 6, 2018

ContraFect to Present at Two Upcoming Investor Conferences

August 29, 2018

ContraFect to Present at ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance

August 22, 2018

ContraFect to Participate in FDA Workshop on Development of Non-Traditional Therapies for Bacterial Infections

August 14, 2018

ContraFect Announces Second Quarter 2018 Financial Results

August 9, 2018

ContraFect Corporation Prices $10 Million Public Offering of Common Stock

July 27, 2018

ContraFect Corporation Announces Proposed Public Offering of Common Stock

July 26, 2018

ContraFect to Present at JMP Securities Life Sciences Conference

June 14, 2018

ContraFect to Present New Data on CF-301 (exebacase) and Lysins Targeting Gram-Negative Pathogens at ASM Microbe 2018

May 30, 2018

RSS
  • « Previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • ...13
  • Next »
© 2019 ContraFect Corporation. All Rights Reserved.
Copyright Privacy Policy Disclaimer Site Map